Corcept Therapeutics Inc (CORT)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Corcept Therapeutics Inc chart...

About the Company

leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis

CEO

Joseph Belanoff

Exchange

NASDAQ

Website

http://www.corcept.com/

$7M

Total Revenue

309

Employees

$3B

Market Capitalization

28.53

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CORT News

Corcept Therapeutics (NASDAQ: CORT)

1d ago, source: The Motley Fool

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and ...

Corcept Therapeutics Inc

2d ago, source: U.S. News & World Report

Are Financial Advisors Worth It? Beyond stock picking, today's advisors help clients plan for a wide range of financial and life goals.

Corcept Therapeutics files patent for treatment of neuroepithelial tumors with non-steroidal SGRA

2d ago, source: Pharmaceutical Technology

Discover a groundbreaking method to treat GR+ neuroepithelial tumors with Corcept Therapeutics Inc.'s patented non-steroidal SGRA treatment. Learn more about this innovative approach today!

Corcept: Q4 Earnings Snapshot

1mon ago, source: seattlepi.com

MENLO PARK, Calif. (AP) — MENLO PARK, Calif. (AP) — Corcept Therapeutics Inc. (CORT) on Thursday reported fourth-quarter earnings of $31.1 million. On a per-share basis, the Menlo Park ...

Corcept Therapeutics Inc HTD

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Corcept Therapeutics Inc CORT

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...